Valeant Pharmaceuticals is forming a committee to delve into the drug company's relationship with the specialty pharmacy Philidor, which was the target of a scathing research report last week. The short-seller research firm Citron said in a report Wednesday that it appears Valeant and Philidor have created a network of phantom pharmacies to trick auditors. Valeant recently revealed that federal prosecutors have subpoenaed documents tied to its drug pricing and other policies.